

# Michael Putman MSci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2250412/publications.pdf>

Version: 2024-02-01

36  
papers

836  
citations

623734  
14  
h-index

501196  
28  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1401  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. Arthritis Care and Research, 2022, 74, 1013-1018.	3.4	4
2	Rapid Adoption of Telemedicine in Rheumatology Care During the <scp>COVID</scp>â€19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. ACR Open Rheumatology, 2022, 4, 128-133.	2.1	6
3	<scp>SARS</scp>â€“<scp>CoV</scp>â€2 Infection and <scp>COVID</scp>â€19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Metaâ€Analysis. Arthritis and Rheumatology, 2022, 74, 766-775.	5.6	117
4	Dr. Conway et al reply. Journal of Rheumatology, 2022, 49, 120.2-121.	2.0	0
5	Where do we go after GiACTA?. Rheumatology, 2022, , .	1.9	0
6	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings, 2022, 97, 250-260.	3.0	10
7	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	3.9	30
8	The impact of COVID-19 on rheumatology trainingâ€”results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.7	7
9	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	1.9	40
10	Challenging wisely: how to move beyond â€1Âmg/kg then taperâ€™. Rheumatology, 2022, 62, 3-6.	1.9	1
11	There is no diagnosis of exclusion in rheumatology. Rheumatology, 2022, , .	1.9	3
12	Benchmarking tocilizumab use for giant cell arteritis. Rheumatology Advances in Practice, 2022, 6, .	0.7	7
13	Any Given Monday: Association Between Desk Rejections and Weekend Manuscript Submissions to Rheumatology Journals. Journal of Rheumatology, 2022, 49, 652-653.	2.0	2
14	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. Journal of Rheumatology, 2021, 48, 1053-1059.	2.0	22
15	Antirheumatic Disease Therapies for the Treatment of COVIDâ€19: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	5.6	52
16	Publication Trends in Rheumatology Systematic Reviews and Randomized Clinical Trials, 1995â€2017. Journal of Rheumatology, 2021, 48, 305-306.	2.0	1
17	Further Investigation of Representation of Women as Authors of Rheumatology Articles From 2005 to 2020: Comment on the Article by Bagga et al. Arthritis and Rheumatology, 2021, 73, 546-547.	5.6	0
18	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatology, The, 2021, 3, e71-e82.	3.9	18

#	ARTICLE	IF	CITATIONS
19	Long-Term Care Resident Awareness and Interest in Spasticity Treatments. <i>Geriatrics (Switzerland)</i> , 2021, 6, 21.	1.7	0
20	The protective effect of rheumatic disease agents in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101659.	3.3	9
21	Authorship Trends in the Rheumatology Literature, 1990â€“2020. <i>Journal of Rheumatology</i> , 2021, 48, 1493-1494.	2.0	1
22	Extensive soft tissue xanthomatosis masquerading as tophaceous gout in a normolipidemic man. <i>Rheumatology</i> , 2021, 60, e381-e383.	1.9	0
23	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1767-1768.	5.6	0
24	Industry Payments to Practicing US Rheumatologists, 2014â€“2019. <i>Arthritis and Rheumatology</i> , 2021, 73, 2138-2144.	5.6	22
25	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
26	Dr. Conway et al reply. <i>Journal of Rheumatology</i> , 2021, , jrheum.210913.	2.0	2
27	Trends in Published Clinical Trial Phases Among Surgical Specialties, 2007â€“2017. <i>Annals of Surgery</i> , 2021, 273, e178-e179.	4.2	2
28	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	3.9	38
29	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	3.9	177
30	Tracking clinical resources for coronavirus disease 2019. <i>Current Opinion in Rheumatology</i> , 2020, 32, 441-448.	4.3	3
31	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	3.4	19
32	Publication Rate and Journal Review Time of COVID-19â€“Related Research. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2290-2291.	3.0	18
33	The Quality of Randomized Controlled Trials in High-impact Rheumatology Journals, 1998â€“2018. <i>Journal of Rheumatology</i> , 2020, 47, 1446-1449.	2.0	5
34	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	3.0	57
35	<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.9	35
36	Learning from Adversity: Lessons from the COVID-19 Crisis. <i>Journal of Rheumatology</i> , 2020, 47, 791-792.	2.0	7